Global impairment of coronary blood flow in the setting of acute coronary syndromes (a RESTORE substudy). Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis.
Acute coronary syndromes result in a global impairment of coronary blood flow with nonculprit artery blood flow being associated with culprit artery flow and vice versa. Improvements in nonculprit artery flow are related to improvements in culprit artery flow after percutaneous intervention; nonculprit arteries with abnormal flow sustain greater improvements in their flow after culprit artery intervention.
Gibson
C M
CM
University of California San Francisco, 94118, USA.
Goel
M
M
Murphy
S A
SA
Dotani
I
I
Marble
S J
SJ
Deckelbaum
L I
LI
Dodge
J T
JT
King
S B
SB
D000789:Angina, Unstable / Q000188:drug therapy / Q000503:physiopathology* / Q000628:therapy; D015906:Angioplasty, Balloon, Coronary; D017225:Atherectomy, Coronary; D003097:Collateral Circulation / Q000187:drug effects; D016001:Confidence Intervals; D003326:Coronary Circulation / Q000187:drug effects / Q000502:physiology*; D003327:Coronary Disease / Q000503:physiopathology; D003331:Coronary Vessels / Q000187:drug effects / Q000503:physiopathology; D004311:Double-Blind Method; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D015999:Multivariate Analysis; D009203:Myocardial Infarction / Q000188:drug therapy / Q000503:physiopathology* / Q000628:therapy; D010919:Placebos; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D012008:Recurrence; D015607:Stents; D000077466:Tirofiban; D016896:Treatment Outcome; D014443:Tyrosine / Q000031:analogs & derivatives* / Q000627:therapeutic use*
D005343:Fibrinolytic Agents; D010919:Placebos; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D014443:Tyrosine; D000077466:Tirofiban